Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Escient Pharmaceuticals Inc.
Headquarters: San Diego, CA, United States of America
Website: N/A
Year Founded: 2017
Status: Acquired
BioCentury | Mar 4, 2025
Deals
Kyorin picks Novartis amid innovative push; Abbvie taps Gubra for obesity: Deals Report
Plus: Hummingbird/Callio, Bridgene/Takeda, Magnet/Lilly, Gensaic/Novo, and more
BioCentury | Nov 19, 2024
Product Development
New oral psoriasis mechanism from Protagonist-J&J yields competitive Phase III data
Also in BioCentury’s latest Clinical Report, CRISPR and RNAi face off in ATTR data from Intellia, Alnylam; plus dermatology setbacks for Incyte
BioCentury | Oct 31, 2024
Finance
Axonis advancing KCC2 program with $115M series A
BioCentury’s Venture Report also includes fundings for Evommune, Blue Earth and more
BioCentury | Oct 11, 2024
Management Tracks
Lilly names Fuchs inaugural chief AI officer
Plus: Turnstone restructures and Glycomine appoints a new chairperson
BioCentury | Apr 30, 2024
Deals
Deals Report: BMS-Repertoire to develop vaccines for autoimmunity
Plus: Regeneron, Mammoth to make CRISPR-based gene editing therapies, and updates from Vertex-TreeFrog, Ono-Deciphera and more
BioCentury | Apr 23, 2024
Deals
Incyte’s hopes for mast cell program spur $750M Escient takeout
Deal gives Incyte clinical molecules for inflammatory, dermatological disorders
BioCentury | Aug 4, 2023
Finance
Biotechs that could enter the IPO queue as crossovers await liquidity
Among dozens of companies that raised crossover cash before markets turned sour, some may soon have what it takes to go public
BioCentury | Dec 1, 2022
Finance
With second asset nearing clinic, Escient to test new mast cell targets with $120M series C
Newly backed by NEA, Abingworth and Forge, the biotech is advancing a MRGPRX2 program for urticaria behind its clinical asset for pruritus
BioCentury | Jun 16, 2022
Management Tracks
New CEOs at Anjarium, Cambridge Epigenetix
Plus Sema4’s CFO to step down, and updates from Marengo, Avilar, City of Hope and more
BioCentury | Jan 7, 2022
Management Tracks
5AM’s Chaurushiya becomes senior partner at Westlake
Plus Berkeley Lights shares sharply lower on CEO transition, Street misses and updates from Anavex, Notable Labs and more
Items per page:
1 - 10 of 19